On this page
- Quick reference
- Dosage chart and four steps
- Supplies needed
- Peptide Reconstitution Simulator
- Vial and research context
- MOTS-C 20 mg Vial and Research Context
- MOTS-C 20 mg Concentration and U-100 Math
- What the 20 mg Vial Strength Changes
- MOTS-C and Mitochondrial Signaling
- Human MOTS-C Findings and Exercise Research
- Preclinical MOTS-C Evidence
- Storage, Handling, and Product Quality
- Research Safety and Measurement Limits
- MOTS-C 20 mg Frequently Asked Questions
- Important Research Context
- References
- Related research, protocols, and guides
MOTS-C Quick Reference (20 mg Vial)
- Vial contents
- 20 mg MOTS-C
- Final volume
- 3 mL
- Concentration
- 6.67 mg/mL
- One U-100 unit
- 66.67 mcg in 0.01 mL
Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read MOTS-c Peptide: Benefits, Uses, Side Effects, Dosage, and Research.
MOTS-C Dosage Chart
Dosing & Reconstitution Guide
20 mg vial calculations and four reconstitution checks
Community-reported use (3 mL = ~6.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) | 3 units (0.03 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 6 units (0.06 mL) |
| Weeks 5–6 | 600 mcg (0.6 mg) | 9 units (0.09 mL) |
| Weeks 7–8 | 800 mcg (0.8 mg) | 12 units (0.12 mL) |
| Weeks 9–10+ | 1,000 mcg (1.0 mg) | 15 units (0.15 mL) |
Community-reported use: Online community descriptions present these rows as once-daily subcutaneous administrations with stepwise increases. Published human research has not validated the dose, frequency, or progression. The rows are shown only to make the vial concentration, U-100 units, and mL arithmetic transparent.
For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light. Follow documented, formulation-specific discard guidance[12].
Supplies Needed
Supply calculations for the displayed 8–16 week daily example; actual laboratory requirements depend on the research design.
-
Peptide Vials (MOTS-C, 20 mg each):
- 8 weeks: approximately 2 vials required
- 12 weeks: approximately 3 vials required
- 16 weeks: approximately 5 vials required
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (2 vials): 6 mL - 1 bottle required (10 mL each)
- 12 weeks (3 vials): 9 mL - 1 bottle required (10 mL each)
- 16 weeks (5 vials): 15 mL - 2 bottles required (10 mL each)
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs - 2 boxes required (100 swabs each)
- 12 weeks: 168 swabs - 2 boxes required (100 swabs each)
- 16 weeks: 224 swabs - 3 boxes required (100 swabs each)
Peptide Reconstitution Simulator
Practice preparing this vial with the verified strength and final volume from this protocol.
MOTS-C Vial and Research Context
- Reconstitute: Add 3.0 mL bacteriostatic water → ~6.67 mg/mL concentration.
- Typical daily range: 200–1,000 mcg once daily (gradual titration over 10 weeks).
- Easy measuring: At 6.67 mg/mL, 1 unit = 0.01 mL ≈ 66.7 mcg on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F) or below; after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); follow documented, formulation-specific discard guidance.
MOTS-c is a 16–amino-acid mitochondrial-derived peptide (MDP) that acts as a metabolic regulator, primarily through AMPK activation[1][2]. Preclinical studies show it enhances insulin sensitivity, promotes fat oxidation, improves exercise capacity, and counters age-related metabolic decline[1][3]. No clinical trials have been completed in humans to date[12]. This educational protocol presents a once-daily subcutaneous approach with gradual titration.
MOTS-C 20 mg Vial and Research Context
A MOTS-C 20 mg vial identifies the total peptide mass in the container. It does not establish an amount per administration. On this page, adding 3.0 mL of bacteriostatic water produces a calculated concentration of about 6.67 mg/mL. That concentration is the basis for the U-100 syringe conversions in the dosage chart, while the displayed schedule remains labeled as community-reported use.
- Vial contents: 20 mg MOTS-C, or 20,000 mcg total.
- Final volume: 3.0 mL after the page’s documented preparation.
- Calculated concentration: 20 mg ÷ 3.0 mL = 6.6667 mg/mL.
- U-100 conversion: 0.01 mL per syringe unit = about 66.7 mcg per unit.
- Evidence boundary: FDA’s technical review found no human exposure data for compounded MOTS-C drug products, so the vial calculation must not be mistaken for a clinically validated injection regimen.[12]
The strength-specific product page documents the 20 mg vial identity and supplier destination; it is product provenance, not clinical evidence.[16]
MOTS-C 20 mg Concentration and U-100 Math
The conversion begins with the unrounded concentration. A 20 mg vial contains 20,000 mcg. Dividing 20,000 mcg by 3.0 mL gives 6,666.7 mcg/mL. Because one U-100 unit is 0.01 mL, each unit contains approximately 66.7 mcg at this preparation.
| Displayed amount | Calculation | U-100 marking | Liquid volume |
|---|---|---|---|
| 200 mcg | 200 ÷ 66.7 | 3 units | 0.03 mL |
| 400 mcg | 400 ÷ 66.7 | 6 units | 0.06 mL |
| 600 mcg | 600 ÷ 66.7 | 9 units | 0.09 mL |
| 800 mcg | 800 ÷ 66.7 | 12 units | 0.12 mL |
| 1,000 mcg | 1,000 ÷ 66.7 | 15 units | 0.15 mL |
These rows restate the arithmetic already shown in the locked primary chart. They do not add a new phase, amount, route, frequency, or duration.
What the 20 mg Vial Strength Changes
Vial strength changes preparation math and theoretical yield. It does not, by itself, determine an appropriate research amount. For the preparation on this page, 20 mg divided across 3.0 mL creates a different concentration from other MOTS-C vial strengths, so the same liquid volume cannot be assumed to contain the same peptide mass.
- Concentration changes: the mass per mL depends on both vial contents and final liquid volume.
- Syringe markings change: U-100 units are volume markings, so they must be recalculated from the concentration.
- Vial yield changes: a larger vial can contain more calculated administrations at the same mass, but handling loss and product-specific limits still matter.
- Evidence does not change: increasing vial mass does not create human dosing evidence or establish safety, effectiveness, or product stability.[12]
MOTS-C and Mitochondrial Signaling
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within mitochondrial 12S rRNA. Early laboratory work connected it with metabolic homeostasis, glucose handling, and resistance to diet-induced metabolic stress in mice.[1] Later reviews describe MOTS-c as part of mitochondrial-to-nuclear communication, with proposed links to AMPK signaling, cellular stress responses, and energy metabolism.[2][9]
Mechanistic findings explain why researchers study the peptide, but they do not validate the community-reported syringe amounts on this page. Cell signaling, animal exposure, naturally circulating human MOTS-c, and an externally supplied research vial are different evidence categories.
Human MOTS-C Findings and Exercise Research
Human research has mainly measured endogenous MOTS-c rather than administering a 20 mg research vial. In one study, exercise increased MOTS-c expression in skeletal muscle and circulating levels in people, while experimental administration and performance findings were studied in mice.[3] A separate acute endurance study measured changes in mitochondrial-derived peptides after exercise in human participants.[4]
Reviews of mitochondrial-derived peptides and exercise describe promising associations with metabolic adaptation, aging, and muscle function, but they also note variable human findings and the need for more direct clinical research.[5][10] These publications provide biological context. They do not establish the dose, frequency, route, escalation, or duration displayed in the community-reported chart.
For a 20 mg research vial, the distinction is practical: no MOTS-C dose is clinically validated, and the effect of an exogenous MOTS-C injection cannot be inferred from exercise-linked changes in endogenous MOTS-C, circulating MOTS-C levels, or plasma MOTS-C measurements.[3][4]
Preclinical MOTS-C Evidence
Animal and cellular models account for much of the published MOTS-c evidence. Ovariectomized mouse research reported changes in adipose homeostasis and metabolic dysfunction.[6] Bone research has examined osteoblast and osteoclast pathways, while broader reviews summarize experimental work involving glucose metabolism, obesity, inflammation, and organ-specific effects.[7][8]
Other reviews place MOTS-c within a larger group of mitochondrial-derived peptides involved in energy metabolism and stress signaling.[9] Research on aging and a recent pancreatic islet cell study expands the list of investigated pathways, but those findings remain model-specific and do not supply a validated human injection protocol.[10][11]
| Evidence type | What it can address | What it cannot establish |
|---|---|---|
| Cell studies | Signaling pathways and molecular responses | Human vial dose, route, frequency, or safety |
| Animal studies | Model-specific metabolism, performance, and tissue effects | A clinically validated human schedule |
| Human observational exercise studies | Endogenous MOTS-c levels and associations | Effects of an injected 20 mg research vial |
| Regulatory review | Known data gaps and product-quality concerns | A positive safety or efficacy conclusion |
Storage, Handling, and Product Quality
The page’s preparation card directs the reconstituted vial to refrigerated storage at 2–8 °C (35.6–46.4 °F), protected from light. Temperature guidance is not the same as a validated shelf life. A discard date requires product-specific labeling, formulation-specific stability evidence, or an applicable sterile-use rule.
- Record the compound, 6.67 mg/mL concentration, and reconstitution date on the vial.
- Use aseptic handling and a new sterile device for each withdrawal.
- Do not infer potency, sterility, or a universal use-by period from refrigeration alone.
- Follow the exact product documentation for storage and discard information when it is available.[16]
FDA’s MOTS-c technical assessment identifies formulation, impurity, aggregation, immunogenicity, and human-exposure uncertainties that cannot be resolved by concentration math.[12]
Research Safety and Measurement Limits
FDA reported that it had not identified human exposure data for compounded MOTS-c drug products and highlighted potential safety risks related to peptide characterization, impurities, aggregation, and immune responses.[12] That evidence ceiling should remain visible when interpreting any community-reported calculation.
MOTS-C is not FDA-approved as a drug, and reported side effects from a standardized human MOTS-C protocol have not been established. Absence of human exposure data is not evidence that a research product is safe.[12]
General subcutaneous injection resources describe skin preparation, site selection, device handling, and sharps disposal, but those sources do not validate MOTS-c or the schedule on this page.[13][14] A literature review of subcutaneous administration also shows that formulation, molecule properties, tissue conditions, and injection volume can influence delivery behavior.[15]
- U-100 units describe liquid volume, not peptide potency or international units.
- Rounding should occur only after calculating from the full concentration.
- Cloudiness, particles, discoloration, or container damage require product-specific review rather than assumptions.
- Preclinical benefit claims should not be presented as established human outcomes.
MOTS-C 20 mg Frequently Asked Questions
What is the MOTS-C dosage for a 20 mg vial?
There is no FDA-approved MOTS-C dosage for a 20 mg vial. The primary chart preserves the site’s existing community-reported calculation sequence and labels it as nonclinical; the vial strength supplies concentration and measurement math, not a validated dose.[12]
Does a 20 mg vial mean a 20 mg administration?
No. The 20 mg label describes total vial contents. The chart converts much smaller displayed microgram amounts using the page’s 3.0 mL preparation.
What concentration results from adding 3.0 mL?
Twenty milligrams divided by 3.0 mL equals 6.6667 mg/mL, commonly displayed as about 6.67 mg/mL.
How much MOTS-C is in one U-100 unit?
At 6.6667 mg/mL, one U-100 unit, or 0.01 mL, contains about 0.0667 mg, which is 66.7 mcg.
Are the displayed amounts supported by human dosing trials?
No. Human studies have primarily measured naturally produced MOTS-c in exercise and aging research.[3][4] FDA’s technical review found no human exposure data for compounded MOTS-c drug products.[12]
Does a larger vial prove a longer usable storage period?
No. Vial mass does not establish a discard date. Storage and use-by decisions require formulation-specific documentation and applicable sterile-handling rules.
Important Research Context
This page separates three different questions: how to calculate a 20 mg vial concentration, what amounts appear in the existing community-reported chart, and what published research has actually tested. The arithmetic is reproducible, but it does not convert observational human findings or animal experiments into a validated human protocol.
Exercise studies support interest in endogenous MOTS-c biology, not a 20 mg vial schedule.[3][4][5] The regulatory assessment documents unresolved human-exposure and product-quality questions.[12] The primary chart therefore remains explicitly labeled as community-reported use and research-reference calculation only.
References
- 1Cell Metabolism (2015): Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.
- 2Journal of Translational Medicine (2023): Wan W, Zhang L, Lin Y, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging.
- 3Nature Communications (2021): Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.
- 4Journal of Applied Physiology (2021): Acute endurance exercise and circulating mitochondrial-derived peptide responses in humans.
- 5Exercise and Sport Sciences Reviews (2021): Mitochondrial-derived peptides and exercise-related metabolic signaling.
- 6Journal of Molecular Medicine (2019): Lu H, Wei M, Zhai Y, et al. MOTS-c regulates adipose homeostasis in an ovariectomized mouse model.
- 7Frontiers in Physiology (2023): Yi X, Hu G, Yang Y, et al. Role of MOTS-c in the regulation of bone metabolism.
- 8Frontiers in Endocrinology (2023): Review of MOTS-c research involving metabolic disorders and experimental disease models.
- 9International Journal of Molecular Sciences (2020): Review of mitochondrial-derived peptides in energy metabolism and cellular stress signaling.
- 10International Journal of Molecular Sciences (2022): Mohtashami Z, Singh MK, Salimiaghdam N, et al. MOTS-c in human aging and age-related disease research.
- 11Experimental & Molecular Medicine (2025): Experimental research on MOTS-c and pancreatic islet cell senescence.
- 12U.S. Food and Drug Administration: MOTS-c bulk drug substance technical review, including human-exposure and product-quality data gaps.
- 13Centers for Disease Control and Prevention: General vaccine administration guidance for the subcutaneous route.
- 14MedlinePlus Medical Encyclopedia: General patient instructions for subcutaneous injection technique and sharps disposal.
- 15Clinical Pharmacokinetics (2019): Review of factors influencing subcutaneous drug delivery and absorption.
- 16Pure Lab Peptides: MOTS-C 20 mg product page for strength identity, supplier information, and available product documentation.
Related research, protocols, and guides
Explore the available research context, protocol variants or comparisons, and practical guides. When vial-strength variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.
Research overview
Other vial-strength protocols
Related protocols and comparisons